Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;79(4):480-4.

Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs

Affiliations

Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs

Dominique Kyelem et al. Am J Trop Med Hyg. 2008 Oct.

Abstract

The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000. To understand why some national programs have been more successful than others, a panel of individuals with expertise in LF elimination efforts met to assess available data from programs in 8 countries. The goal was to identify: 1) the factors determining success for national LF elimination programs (defined as the rapid, sustained reduction in microfilaremia/antigenemia after repeated mass drug administration [MDA]); 2) the priorities for operational research to enhance LF elimination efforts. Of more than 40 factors identified, the most prominent were 1) initial level of LF endemicity; 2) effectiveness of vector mosquitoes; 3) MDA drug regimen; 4) population compliance. Research important for facilitating program success was identified as either biologic (i.e., [1] quantifying differences in vectorial capacity; [2] identifying seasonal variations affecting LF transmission) or programmatic (i.e., [1] identifying quantitative thresholds, especially the population compliance levels necessary for success, and the antigenemia or microfilaremia prevalence at which MDA programs can stop with minimal risk of resumption of transmission; [2] defining optimal drug distribution strategies and timing; [3] identifying those individuals who are "persistently non-compliant" during MDAs, the reasons for this non-compliance and approaches to overcoming it). While addressing these challenges is important, many key determinants of program success are already clearly understood; operationalizing these as soon as possible will greatly increase the potential for national program success.

PubMed Disclaimer

References

    1. Molyneux DH, Zagaria N. Lymphatic filariasis elimination: progress in global programme development. Ann Trop Med Parasitol. 2002;96:S15–S40. - PubMed
    1. Ottesen EA, Bradley M, Hooper PJ, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 Years. PLoS NTDs. 2008 (in press) - PMC - PubMed
    1. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, Shannon WD, Weil GJ. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet. 2006;367:992–999. - PubMed
    1. El-Setouhy M, Abd Elaziz KM, Helmy H, Farid HA, Kamal HA, Ramzy RM, Shannon WD, Weil GJ. The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt. Am J Trop Med Hyg. 2007;77:1069–1073. - PMC - PubMed
    1. De Rochars M, Direny A, Roberts J, Addiss D, Radday J, Beach M, Streit T, Dardith D, Lafontant J, Lammie P. Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs. Am J Trop Med Hyg. 2004;71:466–470. - PubMed

MeSH terms

LinkOut - more resources